See more : Indigenous Roots Corp. (IRCC) Income Statement Analysis – Financial Results
Complete financial analysis of Aarti Pharmalabs Limited (AARTIPHARM.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aarti Pharmalabs Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Nan Pao Resins Chemical Co., Ltd. (4766.TW) Income Statement Analysis – Financial Results
- Shenzhen Investment Holdings Bay Area Development Company Limited (SIHBY) Income Statement Analysis – Financial Results
- SHELTER PHARMA LIMITED (SHELTER.BO) Income Statement Analysis – Financial Results
- Millbank Mining Corp. (MILL.V) Income Statement Analysis – Financial Results
- Wall to Wall Group AB (WTW-TO2-A.ST) Income Statement Analysis – Financial Results
Aarti Pharmalabs Limited (AARTIPHARM.NS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.aartipharmalabs.com
About Aarti Pharmalabs Limited
Aarti Pharmalabs Limited manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, new chemical entities, and xanthine derivatives in India. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is based in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 18.16B | 19.45B | 11.94B | 0.00 | 0.00 |
| Cost of Revenue | 14.25B | 11.70B | 10.01B | 0.00 | 0.00 |
| Gross Profit | 3.91B | 7.75B | 1.92B | 0.00 | 0.00 |
| Gross Profit Ratio | 21.53% | 39.87% | 16.11% | 0.00% | 0.00% |
| Research & Development | 83.70M | 139.61M | 58.16M | 0.00 | 0.00 |
| General & Administrative | 123.87M | 66.17M | 141.31K | 42.00K | 0.00 |
| Selling & Marketing | 679.71M | 588.14M | 261.36M | 0.00 | 0.00 |
| SG&A | 803.59M | 654.30M | 141.31K | 42.00K | 0.00 |
| Other Expenses | 49.00M | 23.20M | 15.90K | 0.00 | 0.00 |
| Operating Expenses | 7.01B | 4.96B | 785.66K | 45.96K | 186.75K |
| Cost & Expenses | 15.38B | 16.66B | 785.66K | 45.96K | 186.75K |
| Interest Income | 30.42M | 9.37M | 57.00K | 0.00 | 0.00 |
| Interest Expense | 172.15M | 210.50M | 1.62K | 0.00 | 0.00 |
| Depreciation & Amortization | 732.35M | 625.43M | 421.19M | 46.00K | 186.75K |
| EBITDA | 3.91B | 3.44B | 2.09B | 40.00 | 0.00 |
| EBITDA Ratio | 21.53% | 17.70% | -0.01% | 0.00% | 0.00% |
| Operating Income | 3.13B | 2.82B | -769.76K | -45.96K | -186.75K |
| Operating Income Ratio | 17.23% | 14.49% | -0.01% | 0.00% | 0.00% |
| Total Other Income/Expenses | -123.20M | -187.34M | -97.82M | 0.00 | 0.00 |
| Income Before Tax | 3.00B | 2.61B | -771.38K | -45.96K | -186.75K |
| Income Before Tax Ratio | 16.55% | 13.41% | -0.01% | 0.00% | 0.00% |
| Income Tax Expense | 835.90M | 672.90M | 331.29M | -46.00K | 0.00 |
| Net Income | 2.17B | 1.93B | -771.38K | -45.96K | -186.75K |
| Net Income Ratio | 11.95% | 9.95% | -0.01% | 0.00% | 0.00% |
| EPS | 23.93 | 21.35 | -0.01 | -0.18 | -0.75 |
| EPS Diluted | 23.93 | 21.35 | -0.01 | -0.18 | -0.75 |
| Weighted Avg Shares Out | 90.64M | 90.63M | 90.63M | 250.00K | 249.00K |
| Weighted Avg Shares Out (Dil) | 90.63M | 90.63M | 90.63M | 250.00K | 250.00K |
Source: https://incomestatements.info
Category: Stock Reports